Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9996630 | 1.00 | REN (0.42) | RENCHEK1CDK2AP1SCN5ASCN9A | |
| SCHEMBL28779405 | 0.90 | REN (0.39) | RENCHEK1CDK2AP1SCN5ASCN9A | |
| SCHEMBL4752797 | 0.88 | KIF11 (0.46) | RENCHEK1CDK2AP1 | |
| SCHEMBL3605975 | 0.88 | REN (0.45) | REN | |
| SCHEMBL28787499 | 0.88 | REN (0.53) | RENCHEK1CDK2AP1SCN5ASCN9A | |
| SCHEMBL3605969 | 0.88 | REN (0.45) | REN | |
| SCHEMBL3610057 | 0.87 | REN (0.42) | RENSCN5ASCN9A | |
| SCHEMBL3613977 | 0.87 | REN (0.42) | RENSCN5ASCN9A | |
| SCHEMBL1866028 | 0.86 | REN (0.46) | REN | |
| SCHEMBL1866030 | 0.86 | REN (0.46) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-101356156-B | Aspartic protease inhibitors | VITAE PHARMACEUTICALS INC | 2012-12-05 | — | — | CN | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| CN-101356156-A | Aspartic protease inhibitors | VITAE PHARMACEUTICALS INC (US) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | REN 180/4885CHEK1 4019/4885CDK2AP1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.